Sarepta reports Q3 GAAP net loss; ESSENCE confirmatory study misses primary endpoint

Sarepta Therapeutics, Inc.

2025-Q3 EPS reported -$4.37 revenue$1,755,303,000

ESSENCE study did not meet primary endpoint (p=0.309); COVID-adjusted analysis showed trend (p=0.09).
Net product revenue $370M (PMO $238.5M, ELEVIDYS $131.5M); total revenue $399.4M, down 15% YoY.
GAAP net loss $179.9M ($1.80 per share) vs net income $33.6M ($0.34) in Q3 2024.
Refinanced convertible debt to 2030; disposed Arrowhead equity; positive cash flow in Q3.
ELEVIDYS labeling discussions with FDA nearing conclusion; non-ambulatory indication removal expected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.